Comparing SAB Biotherapeutics (NASDAQ:SABS) and Genenta Science (NASDAQ:GNTA)

Genenta Science (NASDAQ:GNTA) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Risk & Volatility

Genenta Science has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Institutional & Insider Ownership

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Genenta Science and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
SAB Biotherapeutics	-1,450.14%	-94.04%	-65.68%

Valuation and Earnings

This table compares Genenta Science and SAB Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A
SAB Biotherapeutics	$2.24 million	12.57	-$42.19 million	N/A	N/A

Genenta Science has higher earnings, but lower revenue than SAB Biotherapeutics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genenta Science and SAB Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	0	0	1	0	3.00
SAB Biotherapeutics	0	0	5	0	3.00

Genenta Science presently has a consensus price target of $25.00, suggesting a potential upside of 367.29%. SAB Biotherapeutics has a consensus price target of $12.40, suggesting a potential upside of 306.56%. Given Genenta Science’s higher possible upside, research analysts clearly believe Genenta Science is more favorable than SAB Biotherapeutics.

Summary

Genenta Science beats SAB Biotherapeutics on 8 of the 10 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.